Real-World Clinical Outcomes With Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer

Area of Science:

• Oncology
• Clinical Pharmacology
• Breast Cancer Research

Background:

• Sacituzumab govitecan (SG) is an approved therapy for metastatic triple-negative breast cancer (mTNBC).
• Real-world data are crucial for understanding treatment effectiveness and toxicity in diverse patient populations.

Purpose of the Study:

• To evaluate the real-world clinical effectiveness and toxicity of sacituzumab govitecan (SG) in patients with mTNBC.
• To assess the outcomes of sequential antibody-drug conjugate (ADC) therapy in HER2-low mTNBC.

Main Methods:

• A multi-institution retrospective study included 115 patients with mTNBC treated with SG.
• Demographic, clinicopathologic, and treatment data were collected.
• Survival analyses were performed using Cox regression models.

Main Results:

• The median number of prior therapies was two, with 56% having primary refractory disease.
• Grade 3+ adverse events occurred in 50.9% of patients, including neutropenia and anemia.
• Objective response rate (ORR) was 27.8%, with median overall survival of 9.6 months and progression-free survival (PFS) of 4.8 months.

Conclusions:

• Sacituzumab govitecan (SG) demonstrates clinical activity in a heavily pretreated real-world mTNBC cohort.
• Trastuzumab deruxtecan (T-DXd) showed promising activity after SG in HER2-low mTNBC, supporting sequential ADC use.